1. Home
  2. LOOP vs ALGS Comparison

LOOP vs ALGS Comparison

Compare LOOP & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

HOLD

Current Price

$0.47

Market Cap

39.7M

Sector

Industrials

ML Signal

HOLD

Logo Aligos Therapeutics Inc.

ALGS

Aligos Therapeutics Inc.

HOLD

Current Price

$6.03

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOOP
ALGS
Founded
2010
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
34.6M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
LOOP
ALGS
Price
$0.47
$6.03
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$39.33
AVG Volume (30 Days)
1.4M
127.4K
Earning Date
05-28-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
27.27
88.30
EPS
N/A
N/A
Revenue
$10,889,000.00
$2,186,000.00
Revenue This Year
N/A
$32.20
Revenue Next Year
$174.82
$4.71
P/E Ratio
N/A
N/A
Revenue Growth
7016.99
N/A
52 Week Low
$0.47
$3.98
52 Week High
$1.99
$13.69

Technical Indicators

Market Signals
Indicator
LOOP
ALGS
Relative Strength Index (RSI) 23.96 45.83
Support Level N/A $4.80
Resistance Level $0.97 $6.91
Average True Range (ATR) 0.07 0.56
MACD -0.01 -0.12
Stochastic Oscillator 4.34 16.11

Price Performance

Historical Comparison
LOOP
ALGS

About LOOP Loop Industries Inc.

Loop Industries Inc is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles, packaging, and textiles such as carpets and clothing, into its base building block monomers, DMT and MEG.

About ALGS Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Share on Social Networks: